The use of long-term preventive treatment among people with hereditary angioedema (HAE) was found to significantly reduce the rate of swelling attacks for patients in six countries, according to a new study conducted in North America, Europe, and Australia. Considering the effectiveness of long-term prophylaxis in preventing HAE attacks,…
Ionis Pharmaceuticals has finished enrollment in a Phase 3 clinical trial testing the ability of its experimental therapy donidalorsen to prevent swelling attacks in people with hereditary angioedema (HAE) types 1 or 2. Results from the placebo-controlled study, dubbed OASIS-HAE (NCT05139810), are expected in the first half…
A 22-year-old woman with systemic lupus erythematosus (SLE), the most common form of lupus, developed acquired angioedema (AAE), a recent case report notes. “AAE may happen in adolescents and young adults. It could be an early manifestation of SLE,” the researchers wrote, adding that “practitioners must be aware…
Authorities in Chile have approved Orladeyo (berotralstat) to prevent swelling attacks in hereditary angioedema (HAE) patients 12 and older, marking the therapy’s first marketing authorization in a Latin American country. The preventive, or prophylactic, oral therapy from BioCryst Pharmaceuticals holds similar approvals in the U.S.,…
Nearly half of hereditary angioedema (HAE) patients in the U.K. are on long-term prophylactic treatment to prevent swelling attacks, with more than 80% keeping a supply of on-demand therapies at home to treat sudden flares. That’s according to data from a new national survey that also provided information on…
A 48-year-old man experienced complete remission from hereditary angioedema (HAE) after undergoing a bone marrow transplant for blood cancer, a case study reports. The transplanted stem cells might have given rise to new cells that acted as a healthy source of C1-inhibitor (C1-INH), the protein that is missing or…
An elderly woman developed angioedema about 20 days after being given ticagrelor, a medicine that prevents blood clots from forming and is commonly used to lower the risk of a heart attack or stroke. “Given the uncommon number of cases reported involving ticagrelor-induced angioedema and the even rarer, delayed…
Hereditary angioedema (HAE) Awareness Day is an annual global event held each May 16 to call attention to the disease, which is estimated to affect 1 in 50,000 to 150,000 people worldwide. The day focuses on activities that unite the HAE community and raise awareness among the general…
An experimental gene-editing therapy for hereditary angioedema (HAE), called NTLA-2002, has been administered to the first participant in the Phase 2 portion of a clinical trial, according to its developer, Intellia Therapeutics. “We are pleased to announce dosing has begun in the Phase 2 study of NTLA-2002,”…
A pregnant woman with type 3 hereditary angioedema (HAE) had potential swelling attacks effectively controlled during both pregnancy and breastfeeding with the use of subcutaneous or under-the-skin injections of a plasma-derived C1 esterase inhibitor (C1-INH), according to a case report from Spain. Researchers say this may be the first…
Get regular updates to your inbox.
